Reviewing deficiencies during regulatory inspections can help identify?

Reviewing deficiencies during regulatory inspections can help identify potential gaps in compliance, process inefficiencies, and areas where quality standards may not be fully met. It allows pharmaceutical companies to detect risks before they escalate into major issues, improve documentation practices, and strengthen overall operational control. By analyzing these deficiencies, organizations can implement corrective and preventive actions (CAPA) that enhance product safety, regulatory compliance, and patient trust.

At Knors Pharma, we believe that learning from inspection findings is a proactive step toward building a culture of continuous improvement and maintaining the highest standards of pharmaceutical quality.